Mounjaro NHS Scotland criteria: what the current guidance actually says

You've looked up the criteria and found two different sets of rules

That is not a mistake on your part. NHS England published a staged commissioning plan for tirzepatide under NICE TA1026, opening access in June 2025 to patients with a BMI of 40 or above plus four or more qualifying conditions, and expanding in June 2026 to include people with a BMI of 35 to 39.9 meeting similar criteria. Those numbers are specific to NHS England commissioning and do not automatically translate into Scottish NHS practice.

In Scotland, medicines access for weight management is governed through the NHS Inform Scotland guidance on diabetes and weight-loss medication. The Scottish Medicines Consortium evaluates new medicines independently and advises Health Boards on what to fund. At the time of writing (July 2026), tirzepatide's position within SMC guidance and individual Health Board funding decisions should be confirmed directly with your GP, because availability in NHS Scotland genuinely varies by area and is worth checking before you make any plans. A quick way to check your starting point: call your GP practice and ask whether tirzepatide is currently funded by your local Health Board for weight management, that one question takes under a minute and cuts through a lot of uncertainty.

What does not vary is the clinical evidence. NICE's appraisal of tirzepatide, TA1026, concluded that tirzepatide is clinically effective for adults with a BMI of 35 or above and at least one weight-related comorbidity, with lower BMI thresholds applying for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. That clinical assessment underpins any prescribing decision, wherever you are in the UK.

What the NHS referral pathway in Scotland typically looks like

For most people in Scotland, the path to any NHS-funded weight-management medicine starts with a GP appointment. Your GP assesses your BMI, medical history and weight-related conditions before making a referral to a specialist weight-management service. Those services, often called tier 3 or tier 4 services depending on complexity, then decide which treatment options are appropriate, which could include a GLP-1 medicine if it is funded locally.

This is a slower route than many people expect. Waiting times for specialist weight-management services across Scotland vary considerably and can stretch to months or longer. If your GP practice is not yet participating in any new prescribing arrangements for tirzepatide, or if your Health Board has not yet confirmed funding, the referral pathway can feel like a closed door even when you meet the clinical criteria on paper. For a broader picture of how NHS access differs across the nations, our page on Mounjaro and the NHS in Scotland covers the landscape in more detail.

Conditions that tend to support a referral include type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease, though the list is not exhaustive and clinical judgement always applies. Ethnic-background BMI adjustments recognised in the NICE appraisal should be raised with your GP if relevant to you; not every practice applies them automatically.

Private treatment as an alternative, what it involves and what to check

People who do not meet the current NHS Scotland criteria, or who would rather not wait, often look at private prescription routes. That is entirely legal. Mounjaro is licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, regardless of whether you are on the NHS or with a private provider. The licensing threshold is lower than many NHS funding thresholds, which is why some people are eligible for private treatment before they would qualify through the NHS.

For private access to be legitimate, it must involve a full clinical assessment and a valid prescription from a registered prescriber. Our page on buying Mounjaro online explains what the legal requirements look like in practice and what to check before using any online pharmacy, including how to verify registration on the GPhC register. You can also read about how NHS England's criteria for Mounjaro compare if you are researching both routes.

Cost is a real factor. Private Mounjaro prices have shifted since Eli Lilly raised its UK list price in September 2025; typical private monthly costs since then range roughly £149 to £375 depending on dose and provider, as widely reported at the time. That context is worth holding alongside what NHS access actually offers you in Scotland right now. Our treatment options page sets out what a private consultation involves and what is included in the price.

What NICE TA1026 means for Scottish patients, and what it does not mean

NICE technology appraisals technically apply to England and Wales. Scotland has its own appraisal body, the SMC, and its own formulary decisions. That said, SMC and NICE often reach broadly aligned conclusions on clinical grounds, and a positive NICE appraisal of the kind tirzepatide received in December 2024 tends to inform SMC thinking. If the SMC has issued a positive recommendation for tirzepatide for weight management by the time you read this, your GP will be able to confirm whether your Health Board has accepted it.

One thing TA1026 does establish clearly, for any UK prescriber, is the clinical threshold: adults with a BMI of 35 or above plus at least one weight-related comorbidity, with the ethnic-background adjustment noted above. If you meet those criteria, you have a clinical basis for a conversation with your GP about referral, regardless of current funding decisions. It does not guarantee NHS access, but it is the right starting point.

For more on how the NHS rollout is unfolding and what thresholds are currently active, our overview of tirzepatide in NHS England covers the phase details. If you are curious about the prescription route specifically in Scotland, this page on getting a Mounjaro prescription in Scotland goes further. And if you are weighing up whether private treatment might suit your situation, our weight-loss treatment overview is a good place to start thinking it through. Speak to our prescribers if you would like to understand your private eligibility.